Nigeria's Federal Government has extended N24 billion in tax waivers to pharmaceutical manufacturers across 2025 and 2026, in a bid to cut the country's dependence on imported medicines. Professor Muhammad Ali Pate, Coordinating Minister of Health and Social Welfare, announced the figure on Tuesday at the 3rd Nigeria Health Sector Joint Annual Review in Abuja.

The waivers stem from an Executive Order signed by President Bola Tinubu in 2024 to unlock investment in the healthcare value chain. "The Executive Order signed by Mr President in 2024 has supported N24 billion in tax waivers for pharmaceutical manufacturers in 2025–2026," Pate said.

What does the money actually buy?

The government has commissioned 10 factories and manufacturing lines, six of them in 2026 alone. The facilities span pharmaceuticals, rapid diagnostic tests, long-lasting insecticidal nets (bed nets treated to kill mosquitoes) and medical oxygen.

Pate also cited 12 technology-transfer agreements, with a prospective investment pipeline exceeding $5 billion. The word "prospective" is carrying weight here. The minister himself conceded that the government's task is to translate those commitments into operational businesses capable of supplying safe, effective and affordable products while creating Nigerian jobs. A pipeline, however large on paper, is not yet a factory floor.

Two supporting reforms underpin the strategy:

• Regulatory enforcement. The National Agency for Food and Drug Administration and Control (NAFDAC) is cracking down on falsified medicines, which Pate said strengthens the regulatory environment local manufacturers need.
• Demand consolidation. The government is working to operationalise Medipool, a group purchasing organisation (a body that pools buyers' orders to negotiate better prices) intended to consolidate demand for medicines and health commodities and improve public procurement.

Pate's argument is straightforward: reliable demand and effective regulation matter as much as capital. Without guaranteed purchasers, new manufacturing lines sit idle.

Is local production actually rising?

The Ministry's second claim comes from Dr Iziaq Salako, Minister of State for Health and Social Welfare. He said the share of medicines produced locally rose from 30 per cent in 2023 to 50 per cent in 2026 — a 20-point jump in three years.

Salako attributed the shift to ongoing health sector reforms and investments. Data from the Pharmaceutical Group of the Manufacturers Association of Nigeria and NAFDAC, he added, show roughly a 10 per cent increase in the number of active local pharmaceutical companies over the period.

The figures are notable, but the source is the government grading its own homework; no independent verification was offered at the event, and the baseline for the 50 per cent claim was not detailed.

What does this change for Nigeria's health system?

The measures form part of the administration's broader health sector renewal agenda, which aims to strengthen the healthcare value chain, improve access to essential medical products and build system resilience. For medicine buyers — government procurement agencies, hospitals and patients — the promised payoff is cheaper, more secure supply.

The test now is execution. N24 billion in foregone revenue, 10 commissioned facilities and a $5 billion wishlist only count if the factories run, the agreements convert into plants, and Medipool aggregates demand on schedule. Until NAFDAC publishes production data and the pipeline firms into signed contracts, the 50 per cent milestone remains a ministerial assertion — encouraging, but unconfirmed.